Skip to content
TrialScanner

NCT00141323

Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)

Phase 3CompletedLGNDLead

Registry record

Lead sponsor
Ligand Pharmaceuticals
Conditions
Osteoporosis
Primary completion
Dec 2007Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT00141323 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT00141323: Postmenopausal Evaluation... | TrialScanner